Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

DISEASE CHARACTERISTICS:

Histologically confirmed (by core biopsy) ductal carcinoma in situ

Stage 0 disease
Hormone receptor status not specified

PATIENT CHARACTERISTICS:

Menopausal status not specified
ECOG performance status 0-2
ANC ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9 g/dL
Potassium and magnesium levels normal
Prothrombin time or INR ≤ 1.5 times upper limit of normal (ULN) (unless the patient is receiving therapeutic anticoagulation)
Partial thromboplastin time ≤ 1.2 times ULN (unless the patient is receiving therapeutic anticoagulation)
Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use 2 effective barrier methods of contraception
No known psychiatric or substance abuse disorder that would preclude cooperation with the study requirements
No active hepatitis A, B, or C infection
No active HIV infection
No other active infection
No other malignancy within the past 5 years
No condition that would interfere with the absorption or intake of vorinostat
No history or current evidence of any condition or laboratory abnormality that would confound study results, interfere with the patient's participation in the full duration of the study, or that would not be in the best interest of the patient to participate

PRIOR CONCURRENT THERAPY:

More than 2 weeks since prior IV antibiotics, antivirals, or antifungals
No prior gastrointestinal surgery or other procedure that would interfere with the absorption or intake of vorinostat
No prior or concurrent therapy with any other HDAC inhibitor, including valproic acid
No prior treatment with any other investigational agent
No concurrent systemic steroids
No concurrent anticancer chemotherapy, radiotherapy, biological therapy, or other investigational therapy